Fed. Circ. Questions If Safer OxyContin Profits Came From IP

By Dani Kass · October 7, 2024, 9:39 PM EDT

An attorney for Purdue Pharma didn't seem to find much purchase at the Federal Circuit on Monday as he argued that the company's patents for abuse-deterrent OxyContin weren't obvious, claiming other...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Related Sections

Case Information

Case Title

Purdue Pharma L.P. v. Accord Healthcare, Inc.

Case Number

23-1953

Court

Appellate - Federal Circuit

Nature of Suit

835 Patent - (ANDA) (Fed. Qst.)

Date Filed

May 30, 2023

Featured Stories

Debt Burdens, Revenue Drop Led Pet Care App Wag! To Ch. 11 No Photo Available

Yun Park

Persistent unprofitability, revenue declines related to the COVID-19 pandemic, mounting debt and failed restructuring efforts led the ... (more story)

Data Privacy A Growing Concern In Bankruptcies, Panel Says No Photo Available

Hilary Russ

A panel discussion hosted by the New York City Bar Association touched on data privacy in bankruptcy cases in the wake of 23andMe’s co... (more story)

Under The Radar: Bankruptcy News You May Have Missed No Photo Available

Emlyn Cameron

The Chapter 11 trustee overseeing Chinese exile Miles Guo's bankruptcy won a $33 million mansion for the estate. An insolvent real est... (more story)